FDA approved first topical gene therapy for treatment of wounds in patients with dystrophic epidermolysis bullosa
On May 19, 2023, the U.S. Food and Drug Administration (FDA) approved Krystal Biotech’s Vyjuvek, a herpes-simplex virus…
dystrophic epidermolysis bullosa